Transcranial direct current stimulation to remediate myasthenia gravis
  symptoms by Kamali, Ali-Mohammad et al.
Transcranial direct current stimulation to remediate 
myasthenia gravis symptoms 
 
Ali-Mohammad Kamali 1,2,3,4, Mohammad Reza Hossein Tehrani 3,5, Seyedeh-Saeedeh 
Yahyavi1,2,3,4, Siavash Baneshi3,4, Zahra Kheradmand-Saadi 2,3,6 Masoume Nazeri5, Maryam 
Poursadeghfard5, Mohammad Nami1,2,3,7* 
 
1Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of 
Medical Sciences, Shiraz, Iran  
2DANA Brain Health Institute, Iranian Neuroscience Society-Fars Branch, Shiraz, Iran. 
3Neuroscience Laboratory, NSL (Brain, Cognition and Behavior), Department of Neuroscience, School of 
Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran  
4Student research committee, Shiraz University of Medical Sciences, Shiraz, Iran 
5Clinical neurology research center, Department of neurology, Shiraz University of Medical Sciences, Shiraz, Iran 
6Department of Foreign Languages and Literature, Shiraz University, Shiraz, Iran 
7Academy of Health, Senses Cultural Foundation, Sacramento, USA 
 
Corresponding author  
*Mohammad Nami. Department of Neuroscience, School of Advanced Medical Sciences and Technologies, 
Shiraz University of Medical Sciences, Shiraz, Iran. torabinami@sums.ac.ir 
 
Abstract 
Objective: Myasthenia gravis (MG) is a progressive neurological disease condition 
characterized by fatigue and muscle weakness. Given the potential untoward effects of 
current medications used in the management of MG new non-pharmacological  approaches 
including brain stimulation (namely the transcranial direct current stimulation or, in short, 
tDCS may be considered as potential add-ons to help remediating MG symptoms. 
Methods:  Following a comprehensive neurological and cognitive examinations, ten patients 
with MG were sequentially enrolled and randomly assigned to either sham or real tDCS 
delivered over the primary motor cortex for 20 minutes over the first session. In 48 hours, the 
real arm received sham and the sham arm received real tDCS. After stimulation, the cognitive 
profile of the patients was evaluated through Cambridge Brain Science-Cognitive Platform. 
Later, patients’ muscular strength (eyes, facial muscle, axial and limb muscles) was examined. 
In addition, the maximal muscle power was evaluated through the knee extension exercise 
(1RM) and maximum voluntary contraction (MVC). Likewise, the patients’ muscular endurance 
was recorded through isometric knee extension, sustained hand grip contraction, isometric 
hip and neck flexion, and isometric shoulder extension indices. 
Results: Regarding the muscular strength, real vs. sham tDCS improved 1RM and MVC by 
18.89% and 15.5%, respectively. Moreover, surface electromyography (sEMG) over the 
quadriceps femoris muscle amplitude which was recorded during 1RM task was significantly 
increased after real tDCS by 14.9%. With regard to muscular endurance, the isometric hip and 
neck flexion task score was increased by 66.5 % and17.89 % in real vs sham tDCS arms, 
respectively. In addition, anodal stimulation significantly affected isometric knee (by 18.89%) 
and shoulder (by 36.4%) extension. Meanwhile, the sustained hand grip contraction was not 
significantly influenced by tDCS. 
Conclusions:  Our findings indicated that brain stimulation exerted no effect on the patients’ 
cognitive functions. The study outcome suggest that tDCS over primary motor cortex may be 
considered as a potential non-pharmochological treatment add-on in MG. Larger-sized studies 
need to evaluate the significance of this approach is real-life practice. 
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1. Introduction 
Myasthenia gravis (MG) is a serious and potentially lethal disease causing diurnal 
fatigue and progressive muscle weakness. In general, the condition is classified  as an 
autoimmune disorder[1]. Antibodies found in up to 80-90% of patients with MG[2] are 
known to counteract acetylcholine receptors and eventually destroy them [3]. MG can 
affect males and females of all age groups with the prevalence rate estimated at about 
15 to 179 per one million across studies [4]. 
The diagnosis is based on clinical features and laboratory tests. Symptoms include 
diurnal fatigue fluctuating given the severity of the disease and extent of physical 
activity [3]. There are 2 types of MG where in one type only ocular muscle involvement 
exists, while in another, muscle weakness involves bulbar, limb and axial muscles. The 
extra-ocular muscle weakness is almost asymmetric while limb weakness is symmetric 
and more prominent in proximal parts [3, 4]. In patients with advanced MG, most 
muscles including diaphragm might be affected leading to respiratory failure and 
eventually death. Studies have also shown up to 70-90% decline in  acetylcholine 
receptors due to MG [5]. It has been documented that the thymus gland has a critical 
role in developing MG through T-helper mediated production of anti-acetylcholine 
receptor antibodies. In most MG cases, the thymus size is larger than expected causing 
thymoma in almost 10-25% of patients [5]. 
Thymectomy is then recommended especially in patients with early onset disease and 
without anti-MUSK  and anti LRP4 antibodies [3]. Thymectomy can also be considered 
in patients without thymoma allowing them to achive more favorable treatment 
response[6]. 
In  recent comprehensive review, different currently available and future treatment 
approaches on the basis of MG pathophysiology as well as the auto-antibody  and cell 
response profiles have been outlined [7]. 
 The quantitative evaluation of treatment response questionnaire in MG (QMG), is 
perhaps an essential part of therapeutic response prediction based on the quantitative 
measurement of muscle power and related disease features. Meanwhile, this 
approach may not necessarily be replaced by clinical assessment and should not be 
used classify MG patients. This questionnaire may hence be used for evaluation before 
and during treatment. The MG international committee emphasizes on using all 
components of questionnaire since the diminished muscle power may occur in one or 
two domains though showing remission in the overall disease scale score[8]. 
The current frequently used  medications for MG (e.g.corticosteroids) subject to many 
untoward  effects, therefore, studies have attempted to find alternative solutions owing 
to less side effects as a replacement or add-ons for such treatments [9, 10]. Among 
the more recent non-pharmacological treatment options, transcranial direct current 
stimulation (tDCS) may potentially be considered as a promising approach. The 
technique is intended to deliver direct electrical current to change brain excitability and 
consequently the neuronal activity [11]. In fact, factors such as motor learning, muscle 
strength, fatigue and specific motor skills may be modulated through non-invasive 
brain stimulation approaches including tDCS [12]. tDCS transmits a weak but stable 
electrical current (between 1-2 mA) through surface electrodes to the scalp. The 
duration of intervention typically ranges from 5 to 20 minutes in which the electrical 
current changes the action potential threshold in neurons[13]. With its efficacy and 
safety shown in several neurocognitive cognitions, tDCS may potentially be considered 
as a substitute or add-on for pharmacological treatments in neurocognitive and 
behavioral conditions [14]. 
So far, many studies have shown the effectiveness of  tDCS  for both healthy and 
patient groups, for instance, it was shown to enhance movement training outcome in 
CVA patients [15]. Moreover, tDCS  resulted in better exercise and movement 
outcomes through enhancing motivation as well as reducing exercise fatigue[1]. In the 
present research we hypothesized that tDCS would reduce muscle weakness through 
bypassing the neuromuscular junction impairment (the core underpinning 
pathophysiology in MG) hence improving the motor function. As such, might get clinical 
attention as a promising approach for patients suffering from MG.  
 
 
 
 
2. Method 
2.1. Participants 
 
 Thirteen MG patients who were diagnosed through medical criteria and laboratory 
testing were referred by a neurologist to partake in the study. Three patients were 
excluded from the study because of severe muscle weakness. The study participants 
included 1 male and 9 females aging 18 to 50 years with weight between 40 to 100 
kg who were under MG treatment for at least 3 months prior to the study. Subjects 
were included based on not having any associated illness, MG crisis for at least 3 
month prior to the study, pregnancy, psychological or neurological disorders, and a 
history of alcohol or drug use. An informed written consent was obtained from the 
participants and experimental procedures were approved by the ethical committee at 
Shiraz University of Medical Sciences (approval No. 1396-01-74-15536). Table 1 
outlines the participants’ demographic data.  
participants sex Age disease 
duration 
Medication  
 
Thymectomy Exacerbation MGQOL MMT 
1 F 48 14 1,2 2 0 23      13 
2 F 38 48 1,2 1 2 30       25 
3  M 35 9 1,3 1 0 6       0 
4 F 45 156 1,3 1 4 1       3 
  
2.2. tDCS 
A 2mA electrical current for 20 minutes (ramping up and down for 15 seconds) was 
transferred to the scalp through a two-channel tDCS device (Neurostim-2, Medina Teb). 
The anode electrodes (35Cm2)  were placed over the right (C2, C4, C6, FC2, FC4, FC6) 
and left (C1, C3, C5, FC1, FC3, FC5) motor cortex (10-20 EEG electrode placement 
system). The right motor cortex cathode electrode (16 Cm2) was placed over their right 
shoulder and left motor cortex cathode electrode (16 Cm2) was placed over their left 
shoulder. Sponges soaked in saline (NaCl 150 mM) were used under the electrodes to 
transfer the current. In the sham session, after delivering a 30 second current to cause 
stimulation sensation, the current was switched off. 
 
2.3. Instruments and measurements  
 
- Myasthenia Gravis Activities of Daily Living (MG-ADL): This questionnaire was used to 
evaluate the severity of MG systems [16]. 
 
- Myasthenia Gravis Quality of Life 15-Item Scale (MG –QoL15): This survey was used 
to asses some quality of life factors of MG patients [17]. The patients were supposed 
to report how their disease has affected the 15 items in the survey. The survey retains 
an acceptable construct validity and reliability.  
 
- Manual Muscle Testing (MMT): This questionnaire was used to evaluate the maximal 
power that a muscle could exert [18] 
 
- Quantitative Myasthenia Gravis questionnaire (QMG): It includes different sections 
evaluating double vision, ptosis, swallowing, speech, muscle power of proximal and 
distal parts of upper limbs and proximal part of lower limbs [16]. 
 
- One-Repetition Maximum (1RM)/ Isometric Knee Extension: The assessment is an 
index of the maximal power that a muscle can generate.  This index shows the 
maximum weight that the patients can lift by the knee extension machine. On the other 
hand, the 1RM or one-repetition maximum index was used to assess the maximum 
strength measured through 1RM= 𝑤 (1 +
𝑟
30
), considering 𝑟 >1 (34), where 𝑟 is the 
number of repetitions performed and 𝑤 is the amount of weight. To evaluate isometric 
5 F 39 48 1 1 0 9       17 
6 F 30 24 1,2,3 2 0 17       5 
7 F 31 11 1 1 3 7       0 
8  F 35 48 1,2,3 1 0 11       0 
9 F 43 36 1,2,3 1 3 29      11 
10 F 51 84 1 2 2 35       4 
knee extension, participants were asked to choose 30% of their 1RM and perform the 
knee extension exercise once. The time that they could hold the lift was then recorded. 
 
- Maximum Voluntary Contraction (MVC)/ Sustained Hand Grip Contraction: The 
assessment tests the muscle power in patients suffering from neuromuscular disease. 
MVC was assessed by a hand-grip after both sham and real tDCS sessions. To assess 
the sustained hand-grip contraction, subjects were asked to choose 30% of their MVC 
and perform the hand contraction by a dynamometer (SAEHAN, SH1003). The duration 
they kept gripping the dynamometer  with the specified weight was recorded.  
 
-The Cambridge Brain Science-Cognitive Platform (CBS-CP): The overall cognitive 
profile of the patients was recorded through CBS-CP ( an online platform addressing 
cognitive abilities) after brain stimulation. Three tasks were chosen among the three 
higher-order cognitive components i.e. reasoning, memory and verbal ability [19, 20]. 
Based on the consultation received from a panel of three cognitive scientists,  the Odd 
One Out, Paired Association and Digit Span tasks were selected from the reasoning, 
memory, and verbal domains, respectively. Moreover, the average scores in  each task 
was compared to the mean scores of each task (z-score) within the CBS database. 
 
- Head lift and leg outstretch: The patients were asked to sequentially bend their right 
and left legs at a 45-degree angle. The average time of holding the bent left and right 
legs was recorded as the isometric hip flexion index. Moreover, the duration over which 
patients could hold their neck at a 45-degree angle was considered as the isometric 
neck flexion index.  
 
- Arm Outstretch: the amount of time patients could extend their hands at a 90-degree 
angle was recorded by a chronometer and considered as their isometric shoulder 
extension index. 
 
- Surface Electromyography (sEMG): SEMG was recorded from the rectus femoris 
muscle by a NeXus Biofeedback setup (NeXus 10 MKII, Mind Media). The sensors were 
attached to the midpoint of anterior superior iliac spine and patella through chest leads 
and the sEMG was recorded during the 1RM task. 
 
 
2.4. Data analysis 
To compare the differences between sham and real tDCS (in terms of MVC, sustained 
hand-grip contraction, 1RM, isometric knee extension, sEMG, isometric shoulder 
extension, isometric neck and hip flexion, and CBS-CP), a series of paired sample t-
tests were done. The Mean±SEM (Standard Error of Mean) was considered to report 
any statistical significance in outcomes following the sham and real tDCS sessions. 
The statistically significant p values were set at 0.05. The SPSS statistical package 
(Version 25.0.0, Copyright©IBM) was used for data analysis. 
  
2.3. Experimental design 
At the beginning of the study, every participant was asked to complete the MG-ADL and 
MG-QOL15 to get his/her personal information and disease characteristics recorded. 
The MMT was also used to obtain qualitative evaluations of muscle power before and 
after both sham and real tDCS. All examinations were done by a same neurologist over 
2 sessions as per the instructions in QMG manual [8]. The entire set of questionnaires 
used in the present investigation was originally recommended for clinical research by 
the Task Force of the Medical Scientific Advisory Board- the Myasthenia Gravis 
Foundation of America [21]. Through a single-blind, counter-balanced design, data 
were obtained over two sessions over a 48-hour interval. Through consecutive 
randomization, patients were randomly assigned to sham and real tDCS in order to 
eliminate the learning and practice effects.  Patients were randomly assigned to 2 mA 
sham or real tDCS over the motor cortex for 20 minutes in the first session. After 48 
hours, the group which received sham first, received real tDCS and vice versa. After 
the brain stimulation, to record the patients’ cognitive profiles, subjects were required 
to perform 3 tasks from the CBS-CP components of reasoning, memory and verbal 
abilities. Patients were then asked to hold the hand-grip dynamometer at a 90-degree 
angle for 3 times with the maximum weight they could bear.  The average score of the 
three-time exercises was considered as their MVC. Then, to evaluate the patients’ 
sustained hand-grip contraction, patients were asked to choose 30% of their MVC and 
perform the hand contraction by a dynamometer. The amount of time that they could 
bear the dynamometer with the specified weight was recorded by a chronometer.  
 
 Similarly, the patients were required to perform the knee extension exercise at a 90-
degree angle for at least 6 to 12 times with the maximum weight they could bear with 
the Knee Extension Machine in order to obtain their 1RM. Later, to measure the 
isometric knee extension, patients were asked to choose 30% of their 1RM and hold 
the lift through the knee extension exercise. The duration they could bear the lift was 
recorded by a chronometer. Furthermore, sEMG was recorded during the 1RM 
exercise. Moreover, in order to measure the patients’ isometric hip flexion, the duration 
that they could hold their leg at a 45-degree angle was recorded by a chronometer. 
Likewise, the amount of time they could hold their neck at a 45-degree angle was 
recorded as the patients’ isometric neck flexion.  At the end of the experiment, the 
patients’ arm out stretch indices were also recorded.  
 
 
3. Results 
- 1RM/ Isometric Knee Extension 
With regard to the 1RM used to evaluate the maximal muscular power, the real tDCS 
vs. sham tDCS could increase the muscular strength mean scores by 18.89% (p=0.03). 
Moreover, real tDCS was found to be effective in improving the isometric knee 
extension time by 37.62% (p=0.003) (Figure 1).  
 
- MVC/ Sustained Hand Grip Contraction 
Based on our findings, compared to sham stimulation, the anodal stimulation over the 
motor cortex resulted in a significant increase of the MVC average score by 15.5% 
(p=.003). Meanwhile, the hand-grip contraction time did not show any statistically 
significant change in sham vs. real tDCS session (Figure 1). 
 
 
 - Head Lift and Leg outstretch 
Considering the patients’ lumbar 
and cervical muscular power, it was 
shown that the patients’ leg 
outstretch time could increase by 
66.5 %( p=0.005) following the 
anodal motor cortex stimulation. 
Similarly, the isometric neck flexion 
time improved by 17.89 %( p=0.03) 
after real tDCS (Figure 1). 
 
- Arm Outstretch 
Comparing the isometric shoulder 
extension time after sham and real 
tDCS, findings revealed that the 
anodal stimulation could 
significantly increase the outcome 
by 36.4%(p=0.002) (Figure 1).  
 
- QMG 
Considering the patient’s 
quantitative myasthenia gravis 
testing form sore, it was shown that 
the patients’ QMG score could 
increase by 20.8 %( p=0.01) 
following the anodal stimulation 
over motor cortex (Figure 2). 
 
- sEMG 
The findings revealed that the sEMG 
frequency and amplitude recorded 
during 1RM significantly increased 
after real vs. sham tDCS by 
14.9%(p=0.02) (Figure 3). 
 
- CBS-CP 
In terms of the patients’ cognitive 
performance assessed through 
CBS-CP , results of the paired-
sample t-tests showed no statically 
significant difference between the 
sham and real tDCS sessions in 
terms of memory, reasoning and 
verbal tasks (Figure 4).   
 
 
 However, the average memory (p=.001) and verbal (p=0.01) z-scores in the sham 
session were significantly lower than the mean scores in CBS database (Figure 5). 
 
 
 
 
Figure 1. Dot plots show the MG patients’ muscular strength consisting 1RM and MVC and muscular endurance 
including Isometric hip and neck flexion, isometric knee and shoulder extension, and sustained hand grip 
contraction. Panel (a) indicates a significant difference between the 1RM of the MG patients in sham and real 
tDCS sessions (p <0.05). 1RM is obtained from 1RM= 𝑤 (1 +
𝑟
30
) (𝑟 >1 and is the number of repetitions 
performed and 𝑤 is the amount of weight). Panel (b) shows a significant difference between the MG patients’ 
isometric knee extension time in sham and real sessions (p<0.05). Panel (c) indicates a significant difference in 
MVC (maximum voluntary contraction, the average of holding the hand-grip dynamometer at a 90-degree angle 
with maximum power for 3 times) from sham to real tDCS session (p<0.05). Panel (d) shows no significant 
difference between the patients’ sustained hand-grip contraction time in sessions 1 and 2. Panel (e) shows a 
significant difference between isometric knee flexion time in sessions 1 and 2 (p<0.05). Panel (f) shows a 
significant difference between isometric hip flexion time in sham and real tDCS sessions (p<0.05). Panel (g) 
indicates a significant difference between isometric knee flexion time in sham and real tDCS sessions (p<0.05).  
Paired t-test was used with the p value at .05. n. s., nonsignificant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. It was shown that the 
patients’ QMG score could increase 
(p=0.01) following the anodal 
stimulation over motor cortex 
 
 
Figure 3. This figure represents sEMG of MG patients during 1RM 
exercise. Panels (a) and (b) shows sEMG frequency after sham 
and real tDCS, respectively. The peaks represent lifts during 1RM 
exercise. Comparing panels (a) and (b), real tDCS increased the 
sEMG frequency. Paired t-test was used with the p value at .05. 
n. s., nonsignificant 
 
4. Discussion 
The present findings revealed that tDCS can 
improve MG symptoms, a  disease which is 
characterized by fatigue and muscle weakness 
with the worldwide prevalence of 40-180 million 
people [22]. MG is an autoimmune disease in 
which antibodies are produced against 
acetylcholine receptors in the blood and destroy 
the nicotinic acetylcholine receptors causing 
them to bind to each other, resulting in 
endocytosis of the acetylcholine receptors in 
active synapses [23, 24]. Nearly, all patients with 
MG require treatment [25]. The first line of 
treatment for MG include immune-modulators 
and acetylcholinesterase inhibitors [26] which 
subject to several side effects. So far, no study 
has examined the possible beneficial effects of 
motor cortex stimulation in such patients. The 
majority of MG studies have focused on immune 
system whereas studies on neural aspects in MG 
are scarce. The main research question was to 
examine how much the primary motor cortex 
stimulation may improve motor functions in such 
patients. tDCS is a safe brain stimulation method 
[27]; whereas, the majority of effective 
pharmacotherapies are associated with certain 
complications. Further studies on tDCS may 
potentially introduce it as a complementary 
method to reduce MG symptoms possibly with 
lower required doses of acetylcholinesterase 
inhibitors. tDCS can reduce the stimulation 
threshold of the large pyramidal neurons [28]. It 
is considered as an effective approach in 
improving major depression [29] and a promising 
treatment for generalized anxiety disorder with established effectiveness [30]. tDCS 
may even be used to improve the neurocognitive functionality inhealthy people [31].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Dot plots representing each MG patient’s performance on CBS-CP tasks of reasoning, memory, and verbal abilities 
after sham and real tDCS with the interval of 48 hours. Panel (a) shows no significant difference between the patients’ 
performance on a memory task in sham and real tDCS sessions. Panel (b) indicates no significant difference between the 
patients’ performance on a reasoning task in sham and real sessions. Panel (c) represents no significant difference in a 
memory task scores from sham to real tDCS session. Paired t-test was used with the p value at .05. n. s., nonsignificant. CBC-
CP: Cambridge Brain Science-Cognitive Platform 
 
  
 
MG cannot be effectively managed in 10-15% of the patients who continue to suffer 
from severe immunosuppressive complications [32]. Meanwhile, alternative non-
pharmacological methods can be considered for such patients. Proximal muscle 
weakness is among the important symptoms of MG [33]. In this study, a single session 
of anodic stimulation over motor cortex notably reduced the patients’ weakness. The 
MG-induced muscle weakness after a period of rest or following the administration of 
acetylcholinesterase inhibitors, such as neostigmine or pyridostigmine, is relatively 
remarkable [26]. This suggests that increased acetylcholine concentration in the 
synaptic space can play an important role in reducing the symptoms of the disease 
through inhibition of acetylcholinesterase [34]. In this study, stimulation of the motor 
cortex could plausibly result in more acetylcholine release. This hypothesis would 
however require further research to get tested.  Further studies are needed to 
determine the extent to which more brain stimulation sessions can further improve 
disease symptoms. Patients who participated in the study continued to take their 
medicines prescribed before the study. More controlled studies would be needed to 
show possibility of reducing or discontinuing acetylcholinesterase inhibitors upon  co-
administration of tDCS. The disease was more prevalent in women than men in the 
current study, which is in line with previous studies [35]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Bar graphs representing MG patients’ average performance on CBS-CP tasks of reasoning (Odd One Out), memory 
(Paired Association), and verbal (Digit Span) abilities after sham tDCS and the mean CBS database on these three tasks 
assessed in this study. Panel (a) shows a significant difference between the patients’ performance on a memory task in the 
sham session and the mean CBS database. Panel (b) indicates lower performance of MG patients on a verbal task in the 
sham session compared to the mean CBS database. Panel (c) represents no significant difference between the MG patients 
in the sham session and mean CBS database on a reasoning task. Paired t-test was used with the p value at .05. n. s., 
nonsignificant. CBC-CP: Cambridge Brain Science-Cognitive Platform 
tDCS is a non-invasive treatment probably  with fewer side effects than 
pharmacotherapy. It may be possibly considered as effective in improving the 
symptoms of MG in patients who are medication refractory or intolerant. Moreover, it 
may also be a proper therapeutic solution for patients who do not want to take 
medication. However, our study was subject to some shortcomings including the 
sample size. The lower number of male subjects owing to the higher prevalence of MG 
among women, resulted in a smaller statistical population. Although MG has different 
subgroups [36], this study investigated it as a whole. Furthermore, patients’ brain 
mapping through quantitative electroencephalography (qEEG) while performing 
different cognitive and functional tasks would provide information on neurodynamics 
in future studies. 
 
5. Conclusion 
Taken together, our findings suggest that the anodal stimulation of the primary motor 
cortex  vs. sham may improve MG symptoms and enhance patients’ muscular strength. 
In other words, while tDCS was not effective in improving patients’ cognitive abilities, 
it may be a promising technique for physical empowerment of MG patients. The 
present results may pave the path for neurologists and neuroscientists to establish 
modern techniques for treating MG patients through non-pharmacological methods.  
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